PFBT
AVXL icon

Parkside Financial Bank & Trust’s Anavex Life Sciences AVXL Stock Holding History

Parkside Financial Bank & Trust’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-130
Closed -$400 – 2711
2026
Q1 		$400 Buy
+130
New +$563 ﹤0.01% 2590
2025
Q4 		– Sell
-60
Closed -$534 – 2697
2025
Q3 		$534 Hold
60
– – ﹤0.01% 2551
2025
Q2 		$554 Hold
60
– – ﹤0.01% 2487
2025
Q1 		$515 Buy
+60
New +$567 ﹤0.01% 2364

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Parkside Financial Bank & Trust's AVXL Position: Q2 2026 in Review

Parkside Financial Bank & Trust sold out of Anavex Life Sciences (AVXL) in Q2 2026, closing a stake of 130 shares — an estimated $400 sold.

Parkside Financial Bank & Trust first reported a position in AVXL in Q1 2025 and held it in 4 quarters. The position peaked at $554 in Q2 2025. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Parkside Financial Bank & Trust reported no remaining Anavex Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 130 Anavex Life Sciences shares in Q2 2026, an estimated $400.
  • Parkside Financial Bank & Trust first reported a position in Anavex Life Sciences in Q1 2025 and held it in 4 quarters.
  • Parkside Financial Bank & Trust's Anavex Life Sciences position peaked at $554 in Q2 2025.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.